Dogwood Therapeutics (NASDAQ:DWTX) Receives “Buy” Rating from HC Wainwright

Dogwood Therapeutics (NASDAQ:DWTX)‘s stock had its “buy” rating reissued by analysts at HC Wainwright in a report issued on Friday,Benzinga reports. They presently have a $12.00 target price on the stock. HC Wainwright’s target price suggests a potential upside of 312.37% from the company’s previous close.

A number of other brokerages also recently commented on DWTX. Weiss Ratings restated a “sell (e+)” rating on shares of Dogwood Therapeutics in a report on Monday, December 22nd. Wall Street Zen lowered shares of Dogwood Therapeutics to a “strong sell” rating in a report on Saturday, December 13th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average price target of $12.00.

Dogwood Therapeutics Price Performance

DWTX opened at $2.91 on Friday. Dogwood Therapeutics has a one year low of $2.60 and a one year high of $14.69. The business has a 50 day simple moving average of $3.70 and a two-hundred day simple moving average of $4.95. The firm has a market capitalization of $6.66 million, a price-to-earnings ratio of -0.12 and a beta of 1.88.

Hedge Funds Weigh In On Dogwood Therapeutics

An institutional investor recently bought a new position in Dogwood Therapeutics stock. Marshall Wace LLP acquired a new stake in shares of Dogwood Therapeutics, Inc (NASDAQ:DWTX) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 11,655 shares of the company’s stock, valued at approximately $48,000. Marshall Wace LLP owned 0.51% of Dogwood Therapeutics at the end of the most recent quarter. 9.05% of the stock is owned by institutional investors and hedge funds.

Dogwood Therapeutics Company Profile

Dogwood Therapeutics is a clinical‐stage biotechnology company dedicated to the discovery and development of novel biologic therapies aimed at reducing fibrosis and promoting tissue repair in cardiovascular and other fibrotic diseases. The company leverages a proprietary Discovery Engine that integrates high‐throughput screening, functional genomics and protein engineering to identify and optimize candidate proteins and antibodies with therapeutic potential.

Dogwood’s lead programs are focused on preventing adverse cardiac remodeling following myocardial injury and improving outcomes in heart failure patients.